SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood's stock is trending as investors discuss its potential inclusion in the S&P 500, with the official announcement expected soon. The community is weighing the potential for a short squeeze against the historical trend of stocks dropping after being added to the index. Optimistic traders believe the inclusion, along with upcoming events, will drive the stock higher.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as it joins the S&P 500, sparking excitement and debate about potential short squeezes and future price movement. The community is discussing whether the stock was pumped prior to the announcement and speculating on profit-taking strategies. Some investors express frustration for selling earlier, while others are optimistic about long-term growth.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

GYRO is trending due to its low float, with traders speculating it could be the next stock to experience a significant squeeze. The community is actively discussing its potential for a rapid price increase, drawing comparisons to other low-float stocks that have recently made substantial moves. A recent land sale boosting NAV is also circulating.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

Bed Bath & Beyond is trending as traders discuss the implications of its new ticker symbol and potential connections to blockchain technology through Tzero, drawing comparisons to past meme stock surges like $GME. The community is actively debating whether this is a fresh start or another fleeting rally, and speculating about possible involvement from figures like Ryan Cohen. Some investors believe Overstock's transition to Bed Bath & Beyond, combined with blockchain assets, could drive a significant turnaround.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

aTyr Pharma is trending as investors discuss the potential implications of recent inducement grants and upcoming Phase 3 data, with some speculating about the company's confidence in positive results based on hiring activity. Community perspectives are divided, with bullish arguments emphasizing the potential for a successful outcome and high price targets, while bearish viewpoints focus on past trial data and concerns about short selling strategies. The stock's high short interest and upcoming data readout are contributing to increased volatility and active conversation.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around the token's $SOL.X reward system for holders, emphasizing its potential for passive income. Despite some volatility and past challenges, the community highlights its resilience and the arrival of new developers, sparking renewed optimism. Discussions also focus on upcoming events and partnerships, contributing to the token's visibility.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue ($KVUE) is trending due to discussions surrounding a report linking Tylenol use during pregnancy to autism, sparking community debate about the validity and potential market impact. Some investors view the dip as a buying opportunity, dismissing the report, while others express concern over potential lawsuits and long-term effects on the company. The broader context includes Kenvue's position as a consumer health company and its relationship with Johnson & Johnson.

Pineapple Financial, Inc. is a Canadian based mortgage technology and brokerage company, which engages in the mortgage brokerage services and technology solutions to Canadian mortgage agents, brokers, sub-brokers, brokerages, and consumers. The company also provides back-office services, together with pre-underwriting support services. The company was founded by Shubha Dasgupta, Kendall Marin, and Charles Andrew Green on October 16, 2015 and is headquartered in North York, Canada.

Pineapple Financial Inc

Pineapple Financial ($PAPL) is trending due to a recently closed $100M private placement and a move into Injective (INJ) tokens, sparking high volatility. The community is buzzing about potential short squeezes and halts, with bulls anticipating further upside and bears cautioning about dilution. Traders are closely watching price action and momentum, with some eyeing new entries while others secure profits.

K9 Finance, a Shibarium-based LSD platform, offers core DeFi services and acts as an official validator. Rewarding $KNINE holders with $BONE for block validation, it aims to drive DeFi adoption via the 'Roundtable of Dogs' DAO, which governs treasury and roadmap decisions.

K9 Finance DAO

K9 Finance DAO ($KNINE.X) is trending as the project continues to build on Shibarium, with the community actively discussing staking $BONE for $knBONE and earning rewards through yield farming. The launch of Bonecrusher v3 and the ongoing retro airdrop are also key catalysts driving interest in the project. K9 Finance aims to enhance DeFi within the Shiba Inu ecosystem, focusing on liquid staking and DAO governance.

Enphase Energy, Inc. is a global energy technology company, which engages in the business of designing, developing, manufacturing, and selling home energy solutions that manage energy generation, energy storage, control, and communications on one intelligent platform. It operates through the following geographical segments: the United States, the Netherlands, and Others. The company was founded by Raghuveer R. Belur and Martin Fornage in March 2006 and is headquartered in Fremont, CA.

Enphase Energy Inc

Enphase Energy is trending as investors discuss its potential for recovery amid S&P 500 removal and debates around solar tax credits. Community talking points include the stock's downtrend, possible bottoming, and sensitivity to interest rate cuts, while some express concerns over policy and market conditions. Despite mixed sentiment, there's optimism about Enphase's technology and long-term prospects in the solar energy sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halliburton (HAL) has reportedly been reducing its staff in recent weeks, marking the latest workforce cut in the U.S. oil industry, at a time when costs are rising and oil prices remain low.Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/world-at-work/halliburton-reduces-workforce-oil-activity-slumps-sources-say-2025-09-05/">reported</a> on Friday, citing two sources familiar with the matter, that the scope of Halliburton’s layoffs was unclear. The oilfield services company implemented the cuts over several weeks, sources directly involved in the layoffs told Reuters, adding that at least three business divisions lost between 20% and 40% of their employees.Halliburton, however, did not confirm the layoffs when contacted by the news agency. Texas-based Halliburton had 48,395 employees at the end of 2024, the report noted.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HAL">HAL stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume jumped from ‘normal’ to ‘high’ levels.In July, Halliburton (HAL) CEO Jeff Miller <a href="https://stocktwits.com/news-articles/markets/equity/halliburton-ceo-highlights-pullback-in-oilfield-activity-but-retail-goes-contrarian/ch8MVdqR5ti">said</a> that the oilfield services market will be softer than previously expected over the short to medium term, primarily due to activity reductions in the North American region.“In North America, multiple operators, even large and established customers, are now planning meaningful schedule gaps in the second half of 2025,” Miller said during the company’s second-quarter (Q2) earnings call.The company then said that it expects full-year North America revenue to decline in the low double digits year-over-year and added that full-year international revenue is expected to contract by mid-single digits year-over-year, primarily driven by activity reductions in Saudi Arabia and Mexico.Earlier this week, it was also <a href="https://stocktwits.com/news-articles/markets/equity/conoco-phillips-to-lay-off-up-to-25-precent-of-its-workforce/chwcTx7Rdob">reported</a> that oil company ConocoPhillips is preparing to lay off up to a quarter of its workforce.Halliburton shares have declined 18% year-to-date and have fallen over 23% in the last 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/legend-biotech-considering-second-listing-outside-us-report/chwIifbRdqJ">Legend Biotech Considering Second Listing Outside US: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the logo of Halliburton Company is displayed on a smartphone screen, in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Halliburton Reduces Workforce As Costs Rise Amid Lower Oil Prices: Report

According to a Reuters report that cited sources, at least three business divisions lost between 20% and 40% of employees.

Equity

According to a Reuters report that cited sources, at least three business divisions lost between 20% and 40% of employees.


Ford Motor Co. (F) on Wednesday said that it sold 190,206 vehicles in the U.S. in August, marking a growth of 3.9% year-on-year, owing to strong demand for its SUVs and trucks.While internal combustion engine vehicles continue to dominate the company’s sales numbers, electric vehicle sales jumped 19.3% to 10,671 units in August, while hybrid vehicle sales jumped 14.5% to 18,773 units. The company’s best-selling F series truck, however, witnessed its sales drop 3.4% last month to 68,318 units.The automaker <a target="_blank" rel="noopener noreferrer nofollow" href="https://s205.q4cdn.com/882619693/files/doc_news/2025/Sep/03/Ford-U-S-August-2025-Sales-Release.pdf">sold</a> 105,432 trucks and 81,539 SUVs last month, accounting for a lion’s share of its overall sales.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">Ford stock</a> fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Among SUVs, the Ford Explorer was the best seller, marking a 22% increase in sales to 20,617 units. The Lincoln brand contributed 8,379 units to the company’s overall sales, representing a 14.9% year-over-year decline.Among the company’s three electric vehicles, the Mustang Mach-E SUV was the best-seller, with 7,226 units sold. The company also sold 3,217 units of its electric truck, the F-150 Lightning.In the second quarter, Ford’s EV segment, known as Model e, saw its operating loss widen to $1.3 billion, pressured by tariffs and ramp-up costs at its new Marshall, Michigan, battery plant. For the full year, the company expects an overall net tariff-related headwind of about $2 billion.Ford <a href="https://stocktwits.com/news-articles/markets/equity/ford-ev-investment-5-billion-ceo-jim-farley-model-t-moment/chrHGf7Rde7">stated</a> last month that it plans to introduce a new group of affordable electric vehicles starting in 2027 to expand its EV lineup. The first in line would be a midsize pickup truck assembled at Ford’s Louisville Assembly Plant with an expected starting price of $30,000, the company added.F stock is up by about 17% this year and by about 6% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/waymo-to-begin-testing-robotaxis-in-seattle-denver/chwTyVoRd8F">Waymo To Begin Testing Robotaxis In Seattle, Denver</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A Ford F-150 Lariat PowerBoost ybrid pickup truck is displayed for sale at a Ford dealership on August 21, 2024 in Glendale, California. (Photo by Mario Tama/Getty Images)

Ford Reports Near 4% Jump In US Vehicle Sales In August

The company’s best-selling F series truck, however, witnessed its sales drop 3.4% last month to 68,318 units.

The company’s best-selling F-series truck, however, witnessed its sales drop 3.4% last month to 68,318 units.


United Therapeutics Corporation (UTHR) announced on Tuesday that its study evaluating the use of nebulized Tyvaso Inhalation Solution for the treatment of idiopathic pulmonary fibrosis (IPF) demonstrated improvement in lung function relative to placebo.The late-stage study enrolled 597 patients across multiple locations, and Tyvaso demonstrated superiority over placebo in terms of the change in absolute forced vital capacity by 95.6 mL from baseline to week 52 in patients with IPF. Absolute forced vital capacity (FVC) is a measurement used to gauge lung health, referring to the total volume of air in liters that a person can forcibly exhale after taking a deep, maximum inhalation.Idiopathic pulmonary fibrosis, or IPF, is a scarring disease of the lungs of an unknown cause. It is characterized by the progressive loss of the ability of the lungs to transfer oxygen into the blood, ultimately resulting in respiratory failure and death. United Therapeutics estimates there are over 100,000 IPF patients in the United States.<a href="https://stocktwits.com/symbol/UTHR">UTHR stock</a> traded nearly 36% higher at the time of writing. On Stocktwits, retail sentiment around the shares jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume soared from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:624/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_02_at_12_13_28_PM_png_dae41f310b.webp" alt="UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits" width="624" height="63"><figcaption>UTHR's Sentiment Meter and Message Volume as of 12:13 p.m. ET on Sept. 2, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the positive data implies more funding for more studies.<stembedurl>https://stocktwits.com/DonnyDonowitz/message/627212165</stembedurl>Another user expects the stock to close at $450.<stembedurl>https://stocktwits.com/wallstreet63/message/627228569</stembedurl>United Therapeutics <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.unither.com/press-releases/2025/09-02-2025-120037033">intends</a> to use the data from both the study and an ongoing study of nebulized Tyvaso to support a supplemental New Drug Application to the U.S. Food and Drug Administration (FDA) to add IPF to the labeled indications for nebulized Tyvaso. Data from the ongoing study is expected in the first half of 2026, and the company plans to meet with the FDA before the end of the year to discuss ways to expedite the review process once the data is in, the company said.Following the announcement, multiple analysts hiked their price target on UTHR.<ul style="list-style-type:square;"><li>BofA raised its price target to $463 from $314 and kept a ‘Neutral’ rating on the shares. The firm said that the results were “surprisingly positive” and added that it expects $2.5 billion risk-adjusted peak sales for the drug in IPF.&nbsp;</li><li>Jefferies analyst Roger Song raised the firm's price target to $564 from $432 while keeping a ‘Buy’ rating on the shares.</li></ul>UTHR stock is up by 17% this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bollinger-innovations-stock-plunges-after-announcing-cost-cutting-measures/chv6vkKRdF3">Why Did Bollinger Innovations Stock Plunge 18% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the United Therapeutics Corporation logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

This Pharma Stock Soared 36% Today And Drew Price Target Hikes From Wall Street – More Details Inside

The company reported that Tyvaso demonstrated superiority over the placebo in terms of the change in absolute forced vital capacity, increasing by 95.6 mL from baseline to week 52 in patients with idiopathic pulmonary fibrosis in the trial. 

Shares of EV maker Lucid Group (LCID) traded 3% lower on Friday morning as it gears up for a 1-for-10 reverse stock split. Lucid common stock is expected to begin trading on a split-adjusted basis on Sept. 2, 2025.Retail sentiment around <a href="https://stocktwits.com/symbol/LCID">LCID stock</a> fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘normal’ to ‘low’ levels. According to Stocktwits data, retail chatter around Lucid jumped nearly 43% over the past 24 hours.<figure class="image"><img style="aspect-ratio:577/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_29_at_9_41_13_AM_png_ca794ff972.webp" alt="LCID's Sentiment Meter and Message Volume as of 9:41 a.m. ET on Aug. 29, 2025 | Source: Stocktwits" width="577" height="61"><figcaption>LCID's Sentiment Meter and Message Volume as of 9:41 a.m. ET on Aug. 29, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expects that the stock to dive 50% after the reverse split.<stembedurl>https://stocktwits.com/Stocktracker32/message/626982440</stembedurl>Another user, however, said that they see the stock rallying up to $12 to $15.<stembedurl>https://stocktwits.com/JD108/message/626983876</stembedurl>Separately, Stifel on Friday lowered the firm's price target on Lucid to $2.10 from $3 while keeping a ‘Hold’ rating on the shares. Stifel highlighted that it still views the Air sedan and Gravity SUV as "excellent products," but added that it expects additional capital to be required over the next few years. The brokerage also awaits clarity on Gravity sales and the rollout of the midsize vehicle, as per TheFly.The Air and Gravity models are premium segment vehicles. The midsize SUV is expected to be priced lower, around $50,000, thereby expanding the company’s total addressable market. The vehicle is expected to be launched in 2026.LCID stock is down by 33% this year and by 49% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/citi-lowers-price-target-on-li-auto-after-disappointing-q3-guidance/chtTiaDRdNQ">Citi Lowers Price Target On This Chinese EV Maker After Disappointing Q3 Guidance: Retail Expects Shares To ‘Eventually Implode’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

The 2025 Lucid Gravity electric sports utility vehicle (SUV) is displayed during the 2023 Los Angeles Auto Show at the Los Angeles Convention Center. (Photo by Josh Lefkowitz/Getty Images)

Lucid Stock Gets A Price Target Cut From Stifel As It Gears Up For A Reverse Stock Split: Retail Sees 50% Dive Post Split

Lucid common stock is expected to begin trading on a split-adjusted basis on Sept. 2, 2025.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Wednesday said that it has approved Biogen Inc.’s (BIIB) Zuranolone to treat moderate or severe postnatal depression (PPD) in adults following childbirth.Postnatal depression is a type of depression that many parents experience after having a baby and is marked by feelings of sadness, irritability, anxiety, loss of interest, extreme fatigue, appetite changes, among others. One in every ten women is affected by postnatal depression within a year of childbirth, as <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.gov.uk/government/news/mhra-approves-zuranolone-to-treat-postnatal-depression-in-adults-following-childbirth">per </a>MHRA.Biogen’s Zuranolone, under the brand name Zurzuvae, is the first oral treatment for postnatal depression approved in the UK, the agency said.The drug comes as a capsule and should be taken orally at night with a fat-containing meal for 14 days. Common side effects of the medicine include memory impairment, confusion, and fatigue, among others.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> trended within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Zurzuvae last month in the European Union. The drug was approved by the U.S. Food and Drug Administration in 2023. According to Biogen, an estimated 5-20% of women with a pregnancy experience symptoms of PPD in Europe.Zurzuvae was discovered by Sage Therapeutics Inc. (SAGE). In 2020, Biogen and Sage Therapeutics entered into a collaboration to jointly develop and commercialize Zurzuvae in the U.S. As part of the agreement, Biogen received exclusive rights to develop and commercialize Zurzuvae outside of the U.S., excluding Japan, Taiwan, and South Korea.In the second quarter, Biogen reported revenue of $46.4 million from Zurzuvae, up from $14.9 million in the corresponding quarter of 2024, driven by increased demand.BIIB stock is down by 10% this year and by about 32% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-suncar-technology-stock-rallying-today/chsUeO7RdlB">Why Is SunCar Technology Stock Rallying Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

UK Regulator Approves Biogen’s Drug For Treating Postnatal Depression

Zuranolone is the first oral treatment for postnatal depression approved in the UK, the agency said. 

Ford Motor Co (F) is recalling 355,656 trucks in the U.S., citing concerns that the instrument panel cluster may fail at startup, the National Highway Traffic Safety Administration (NHTSA) said on Wednesday.An instrument panel display that does not show critical information, such as warning lights or vehicle speed, can increase the risk of a crash, the U.S. auto safety regulator <a target="_blank" rel="noopener noreferrer nofollow" href="https://static.nhtsa.gov/odi/rcl/2025/RCLRPT-25V540-5865.pdf">said</a>.The recall includes certain model year 2025-2026 trucks, including the F-550 SD, F-450 SD, F-350 SD, F-250 SD, and F-150.The company will fix the issue by updating the instrument panel cluster software through a dealer or via an over-the-air update. The fix would be free of cost to the customer.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/F">Ford stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_at_6_50_50_AM_png_b23bf72a57.webp" alt="F's Sentiment Meter and Message Volume as of 6:50 a.m. ET on Aug. 27, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>F's Sentiment Meter and Message Volume as of 6:50 a.m. ET on Aug. 27, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they see multiple potential catalysts for the stock, including strong August sales, a September rate cut, and more information on the company’s new electric vehicle platform, among others.<stembedurl>https://stocktwits.com/Hughknowthedeal/message/626674748</stembedurl>Another noted that the issue will be resolved via a software update.<stembedurl>https://stocktwits.com/Hughknowthedeal/message/626673325</stembedurl>Ford is aware of 95 warranty claims related to the issue as of June 26, the NHTSA said. However, the company added that it was not aware of any accident or injury reports related to the condition.F stock is up by 20% this year and by over 6% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/goldman-sachs-sees-brent-oil-prices-falling-to-low-50s-on-rising-inventories/chsxU9BRdks">Goldman Sachs Sees Brent Oil Prices Falling To Low-$50s On Rising Inventories</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Ford Issues Nearly 356,000 Vehicles Recall In US, But Retail Investors Spot Emerging Catalysts

The U.S. auto safety regulator said that an instrument panel display that does not show critical information, such as warning lights or vehicle speed, can increase the risk of a crash.

Ford Issues Nearly 356,000 Vehicles Recall In U.S., But Retail Investors Spot Emerging Catalysts

The U.S. auto safety regulator said that an instrument panel display that does not show critical information, such as warning lights or vehicle speed, can increase the risk of a crash.


Regeneron Pharmaceuticals, Inc. (REGN) announced on Tuesday that the late-stage trial evaluating its investigational Cemdisiran monotherapy in adults with generalized myasthenia gravis (MG) yielded positive results.MG is a rare and chronic autoimmune disease where disrupted communication between nerves and muscles results in debilitating and potentially life-threatening muscle weakness. According to Regeneron, the disease impacts approximately 85,000 people in the U.S.Both Cemdisiran and the combination of Cemdisiran and the approved antibody Pozelimab (cemdi-poze) demonstrated improvements in activities of daily functioning such as talking, eating, breathing, vision, and mobility at week 24. Cemdisiran showed numerically better results across all generalized myasthenia gravis-specific outcomes, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/regeneron-announces-positive-results-phase-3-trial-generalized">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels. Shares of the company traded 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:576/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_26_at_12_07_06_PM_png_ed2effdb15.webp" alt="REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits" width="576" height="61"><figcaption>REGN's Sentiment Meter and Message Volume as of 12:07 p.m. ET on Aug. 26, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user believes that the stock may hit an all-time low soon.<stembedurl>https://stocktwits.com/Johny34211/message/626531477</stembedurl>The firm said that treatment-emergent adverse events (TEAEs) occurred in 69% of patients treated with Cemdisiran, 81% with cemdi-poze, and 77% with placebo. Serious TEAEs occurred in 3% of patients treated with Cemdisiran, 9% with cemdi-poze, and 14% with placebo, the company said. However, there were no treatment discontinuations due to adverse events through week 24 in the Cemdisiran arm, it added.The company also said that there were no deaths during the 24-week placebo-controlled portion of the trial. During the extension period, however, one death due to pneumonia occurred in the Cemdisiran arm, and one death due to septic shock occurred in the combination arm. Both deaths occurred in patients who were on concomitant immunosuppressive therapies, Regeneron said.The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the U.S. Food and Drug Administration (FDA).REGN stock is down by 18% this year and by 51% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/jpmorgan-upgraded-nio-shares-with-price-target-hike/chsHCIGRdjA">This Chinese EV Stock Surged 8% Today And JPMorgan Just Upgraded The Shares With A Price Target Hike: Retail Eyes $10 By End Of Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon

The company now plans to apply for regulatory approval in the U.S. for Cemdisiran in the first quarter of 2026, pending discussions with the FDA.

Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older.The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season this fall. The firm <a target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=5951824473215334&amp;symbol=MRNA">added</a> that the pre-filled syringe doses of the vaccine for the market will be made domestically. While the drug substance will be produced at the company’s facility in Laval, Quebec, fill-finish operations will be completed by Novocol Pharma in Cambridge, Ontario.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRNA">Moderna</a> jumped from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels. Shares of the company traded 5% higher on Friday morning at the time of writing.Health Canada authorized the vaccine based on clinical, non-clinical, and real-world data supporting the vaccine’s safety and efficacy, Moderna said. The updated vaccine targets the SARS-CoV-2 LP.8.1 variant.While those Canadians covered by public programs will receive the vaccine free of charge, the company is also working with private insurers and payers to streamline access and reimbursement within the private sector, it said. The updated COVID-19 vaccine has already been approved by regulators in Europe, Japan, Switzerland, and other countries. Applications are also under review in other markets.In the second quarter, Moderna reported $114 million in Spikevax sales, including $88 million of U.S. sales and $26 million of international sales. Spikevax sales accounted for 80% of the company’s total revenue in the three months through the end of June.MRNA stock is down by 34% this year and by about 66% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ulta-beauty-gets-upgraded-to-overweight-by-barclays/chsZPwFRd0U">Ulta Beauty Gets Upgraded To ‘Overweight’ By Barclays, But Retail Sentiment Cools Ahead Of Earnings</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Moderna headquarters, exterior view, Cambridge, Massachusetts, USA. (Photo by: Plexi Images/GHI/UCG/Universal Images Group via Getty Images)

Moderna Gets Clearance To Deliver Updated Spikevax COVID-19 Vaccine In Canada

The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season.

Regeneron Pharmaceuticals, Inc. (REGN) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has extended the date by which it is expected to rule on two of its EYLEA HD Injection regulatory submissions.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.regeneron.com/news-releases/news-release-details/eylea-hdr-aflibercept-injection-8-mg-applications-expanded-us">said</a> that the FDA will now decide on its submissions by the fourth quarter of 2025. The agency extended review time after determining that information provided since the completion of a recent inspection of a third-party manufacturer constituted a major amendment to each submission. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/REGN">REGN</a> remained within the ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.Regeneron had submitted applications pertaining to the EYLEA HD prefilled syringe and another seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications. The delay, however, was <a href="https://stocktwits.com/news-articles/markets/equity/truist-cuts-price-target-on-regeneron-citing-near-term-investor-focus-on-eylea/chrHEcxRdeF">anticipated</a>, the company said.The firm said it resulted from observations during an FDA general site inspection at Catalent Indiana LLC, &nbsp;the filler for these regulatory applications.Novo Nordisk recently acquired Catalent. The firm submitted a response earlier this month to address the observations noted by the FDA. Regeneron said that the FDA will be able to act on its applications once the manufacturing issues are resolved. The FDA was previously expected to decide on the submissions by August 2025.EYLEA HD, however, remains available in the U.S. through vial administration and is approved to treat vision-threatening conditions that impact patients, such as wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).REGN stock is down by 17% this year and by about 51% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Regeneron Says FDA Will Take More Time to Review Its Two Eylea HD Submissions

The company said that the FDA will now decide on its submissions by the fourth quarter of 2025.

Kerrisdale Capital on Tuesday revealed a short position on autonomous trucking company Aurora Innovation (AUR), alleging that the firm does not have a viable business model.Kerrisdale <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.kerrisdalecap.com/wp-content/uploads/2025/08/Kerrisdale-Aurora.pdf">said</a> that the market for autonomous trucking is far too small and the profit pool available to Aurora from it is “puny.” Shares of AUR fell 7% on Tuesday morning. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AUR">Aurora</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.Kerrisdale said that Aurora’s self-driving architecture will never enable point-to-point shipping. It said that the best-case scenario is a hub-and-spoke freight system in which driverless trucks travel between terminals immediately adjacent to highways, and last-mile manned shippers pick up and drop off shipments from and to individual customers.The firm noted that in trips less than 1,500 miles, autonomous trucking is too slow and expensive compared to manned trucking. Hence, when cutting out trips less than 1,500 miles, the entire market for autonomous trucking is just 1/10th of Aurora's claimed total addressable market of $200 billion, it said.Kerrisdale pointed out that Aurora wants to sell just software, but hub-and-spoke freight services require hub infrastructure, which requires billions in investment. While Aurora is optimistic that some other firm will step up to put up the physical hubs, no one has till now, it said.Meanwhile, executives at Volvo and Paccar, Aurora’s partners for physical trucks, told Kerrisdale that autonomous trucks will cost at least 50% more than regular trucks. In addition, there is competition from players including Daimler-Torc, Waabi, and Kodiak, who are taking a lower-cost approach, it added. “Autonomous trucking is a niche market, and Aurora will have to split it with better-positioned truck/component manufacturers, hub developers, logistics operators, and competition. $AUR should trade like a speculative small cap, and we think it will,” the short seller said while warning investors that they should “expect a decade of continuous dilution before arriving at a dead end.”AUR stock is down by 5% his year but up by about 58% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/vktx-stock-in-spotlight-on-high-dropout-rate-in-oral-weight-loss-drug-study/chsgSlCRdgY">This Drugmaker Stock Slumped 36% In Tuesday’s Premarket Session: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Autonomous vehicle from Aurora Innovation driving along University Avenue, with storefronts and tree-lined street in the background, Palo Alto, California, July 11, 2024.

Short Position Revealed! Aurora Stock Slides After Kerrisdale Capital Says Company Doesn’t Have Viable Business Model

Kerrisdale Capital on Tuesday revealed a short position on autonomous trucking company Aurora Innovation (AUR), alleging that the firm does not have a viable business model.

Aurora Stock Slides After Kerrisdale Capital Says Company Doesn’t Have Viable Business Model

The firm said that the market for autonomous trucking is far too small and the profit pool available to Aurora from it is “puny.”

Current Price	$86.85
Prev Close	$86.48
Open	$86.71
Dividend Yield	N/A
50-Day Moving Average	$86.89
Beta	N/A
Avg. Volume	219,288.05
PE Ratio	N/A

52-Week High	$89.65
52-Week Low	$68.68
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

AVUS
American Century ETF Trust - Avantis U.S. Equity ETF

Feed

News

Sentiment

Fundamentals

Info

Latest AVUS News

AVUS American Century ETF Trust - Avantis U.S. Equity ETF